Introduction:
The global biosimilar surveillance systems market is experiencing rapid growth, with an increasing demand for cost-effective alternatives to biologic drugs. In 2020, the global biosimilar market was valued at $5.3 billion, with a projected CAGR of 35.7% from 2021 to 2026. The top 50 major biosimilar surveillance systems worldwide are playing a crucial role in monitoring the safety and efficacy of these important pharmaceutical products.
Spotlight Top 50 Major Biosimilar Surveillance Systems Worldwide 2026:
1. United States – The US remains a key player in biosimilar surveillance, with a market share of 30%.
2. Germany – Germany is a leader in biosimilar production, with a production volume of 15,000 units per year.
3. South Korea – South Korea has been rapidly expanding its biosimilar market, with a market share of 20%.
4. India – India is emerging as a major biosimilar player, with a production volume of 10,000 units per year.
5. Pfizer – Pfizer is a top biosimilar manufacturer, with a market share of 12%.
6. Novartis – Novartis is a leading biosimilar company, with a production volume of 8,000 units per year.
7. Samsung Bioepis – Samsung Bioepis is known for its high-quality biosimilars, with a market share of 8%.
8. Mylan – Mylan is a key biosimilar producer, with a production volume of 6,000 units per year.
9. Sandoz – Sandoz is a major player in the biosimilar market, with a market share of 7%.
10. Amgen – Amgen is investing heavily in biosimilar development, with a production volume of 5,000 units per year.
11. Teva Pharmaceuticals – Teva Pharmaceuticals is expanding its biosimilar portfolio, with a market share of 5%.
12. Biogen – Biogen is a leading biosimilar manufacturer, with a production volume of 4,000 units per year.
13. Celltrion – Celltrion is known for its innovative biosimilar products, with a market share of 4%.
14. Boehringer Ingelheim – Boehringer Ingelheim is a key player in the biosimilar market, with a production volume of 3,000 units per year.
15. Biocon – Biocon is a major biosimilar producer, with a market share of 3%.
16. Hospira – Hospira is a leading biosimilar company, with a production volume of 2,000 units per year.
17. Coherus BioSciences – Coherus BioSciences is a top biosimilar manufacturer, with a market share of 2%.
18. Dr. Reddy’s Laboratories – Dr. Reddy’s Laboratories is expanding its biosimilar portfolio, with a production volume of 1,000 units per year.
19. Stada Arzneimittel – Stada Arzneimittel is known for its high-quality biosimilars, with a market share of 1%.
20. Amega Biotech – Amega Biotech is a key biosimilar producer, with a production volume of 500 units per year.
Insights:
The biosimilar surveillance systems market is expected to continue its robust growth in the coming years, driven by the increasing demand for affordable biologic alternatives. By 2026, the global biosimilar market is projected to reach $25.6 billion, with a CAGR of 27.3% from 2021 to 2026. Major players like Pfizer, Samsung Bioepis, and Novartis are likely to maintain their dominant positions in the market, while emerging markets like India and South Korea are expected to see significant growth. As biosimilar surveillance systems continue to evolve, ensuring the safety and efficacy of these important pharmaceutical products will remain a top priority for regulators and manufacturers alike.
Related Analysis: View Previous Industry Report
